Literature DB >> 23282980

Clinical efficacy and safety of a combined loratadine-betamethasone oral solution in the treatment of severe pediatric perennial allergic rhinitis.

Teolinda Mendoza de Morales1, Francis Sánchez.   

Abstract

BACKGROUND: : Allergic rhinitis is a highly prevalent condition, particularly among children, whose schoolwork and quality of life may be impaired by its symptoms.
METHODS: : In this prospective, multicenter study, children between 6 and 12 years old with a diagnosis of severe perennial allergic rhinitis received a combination of the nonsedating antihistamine loratadine and the corticosteroid betamethasone in an oral solution for 5 days.
RESULTS: : The total nasal and ocular symptom score was significantly reduced from 11.4 (±2.1) before treatment to 2.9 (±2.4) after treatment (P < 0.01). Significant reductions (P < 0.01) were also observed for sneezing, nasal pruritus, nasal congestion, rhinorrhea, postnasal drip, and ocular erythema and pruritus. No adverse events were reported, and no subject discontinued treatment.
CONCLUSIONS: : The combination of loratadine and betamethasone in an oral solution was safe and effective as initial short-term treatment for symptoms of severe perennial allergic rhinitis in school-aged children.

Entities:  

Year:  2009        PMID: 23282980      PMCID: PMC3651010          DOI: 10.1097/WOX.0b013e31819f2105

Source DB:  PubMed          Journal:  World Allergy Organ J        ISSN: 1939-4551            Impact factor:   4.084


  29 in total

Review 1.  Allergic rhinitis and its impact on asthma.

Authors:  J Bousquet; P Van Cauwenberge; N Khaltaev
Journal:  J Allergy Clin Immunol       Date:  2001-11       Impact factor: 10.793

Review 2.  Measuring health-related quality of life in rhinitis.

Authors:  E F Juniper
Journal:  J Allergy Clin Immunol       Date:  1997-02       Impact factor: 10.793

3.  Allergic and nonallergic rhinitis: their characterization in a tropical environment.

Authors:  D Perdomo de Ponce; M Uribe; I Wolff
Journal:  Invest Clin       Date:  1990       Impact factor: 0.683

4.  Pathophysiology of nasal obstruction and meta-analysis of early and late effects of levocetirizine.

Authors:  J Patou; H De Smedt; P van Cauwenberge; C Bachert
Journal:  Clin Exp Allergy       Date:  2006-08       Impact factor: 5.018

Review 5.  Allergic rhinitis update: Epidemiology and natural history.

Authors:  J A Bellanti; D B Wallerstedt
Journal:  Allergy Asthma Proc       Date:  2000 Nov-Dec       Impact factor: 2.587

6.  A multicentre study of loratadine, clemastine and placebo in patients with perennial allergic rhinitis.

Authors:  L Frølund; B Etholm; K Irander; T A Johannessen; L Odkvist; B Ohlander; B Weeke
Journal:  Allergy       Date:  1990-05       Impact factor: 13.146

7.  A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis.

Authors:  P H Ratner; J H van Bavel; B G Martin; F C Hampel; W C Howland; P R Rogenes; R E Westlund; B W Bowers; C K Cook
Journal:  J Fam Pract       Date:  1998-08       Impact factor: 0.493

8.  Rhinitis management: the patient's perspective.

Authors:  E F Juniper
Journal:  Clin Exp Allergy       Date:  1998-12       Impact factor: 5.018

9.  Intranasal steroid aerosol in perennial rhinitis: comparison with an antihistamine compound.

Authors:  S M Harding; S Heath
Journal:  Clin Allergy       Date:  1976-07

10.  Delayed genomic and acute nongenomic action of glucocorticosteroids in seasonal allergic rhinitis.

Authors:  H-C Tillmann; B A Stuck; M Feuring; K Rossol-Haseroth; B M Tran; R Lösel; B M Schmidt; K Hörmann; M Wehling; A Schultz
Journal:  Eur J Clin Invest       Date:  2004-01       Impact factor: 4.686

View more
  1 in total

1.  Treatment of allergic rhinitis with desloratadine: results of a multinational observational study in the middle East gulf region.

Authors:  Tamer M H Adham
Journal:  World Allergy Organ J       Date:  2011-08       Impact factor: 4.084

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.